Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

GSK plc（伦敦证券交易所/纽约证券交易所代码：GSK），一家市值673.5亿美元、目前交易价格接近52周低点的知名制药公司，今天公布了其FIRST三期临床试验的积极结果。该试验评估了Zejula（尼拉帕利）和Jemperli（dostarlimab）在治疗晚期卵巢癌方面的效果。

GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...

Infinity Sports Al Johnson & Johnson's Zejula has been granted breakthrough drug status by the US FDA and has entered priority review in mainland Chi ...